Locations:
Search IconSearch

Tag: mavacamten

Obstructive hypertrophic cardiomyopathy

REMS Update: Mavacamten Still Effective in Treating Real-World Patients With HCM

Few patients report left ventricular dysfunction or heart failure after one year

cardiac MRI showing obstructive hypertrophic cardiomyopathy

Final VALOR-HCM Report: At 128 Weeks, Mavacamten Sustains Gains in HCM Patients

Avoidance of septal reduction therapy continues while LVEF dysfunction remains infrequent

echocardiogram showing strain imaging assessment

Mavacamten’s Effects on Strain Imaging in Obstructive HCM: Insights From VALOR-HCM

Serial strain assessments show sustained favorable impacts on LV systolic function and LA function

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

22-HVI-3393756_echo-showing-obstructive-HCM_ 650×450

VALOR-HCM Substudy: Mavacamten Improves Left Ventricular Diastolic Function

Gains are associated with clinical and biomarker benefits in obstructive HCM

22-HVI-2769712_hyptertrophic-cardiomyopathy_650x450

Mavacamten Significantly Reduces Patients’ Need for Septal Reduction Therapy Over 16 Weeks

Longer-term confirmation of VALOR-HCM could yield a noninvasive therapy for severe obstructive HCM

cardiac magnetic resonance images showing hypertrophic cardiomyopathy

Hypertrophic Cardiomyopathy: Signs of Progress Toward a Medical Therapy and Refined Risk Prediction

New and ongoing studies aim to reduce the need for surgery, improve risk stratification

BackPage 1 of 1Next

Advertisement

Ad